David Conlon

David Conlon

Company: Daiichi Sankyo, Inc.

Job title: Senior Director, CMC Management and Operations


  • Key member of the technical teams that transferred the asthma drug Singulair® and the antifungal Cancidas® from the Merck Research Laboratories to the manufacturing division.
  • Established the strategy and directed the activities of a team of over 20 scientists who took a holistic approach to design a completely de novo synthesis of the antiretroviral clinical candidate BMS-663068-03 that resulted in a significant improvement in the efficiency of the synthesis with an increase in the overall yield from 2.3% to 12.3%.
  • Directed the activities of multiple teams that were responsible for global, cross-functional projects that delivered drug substance and the required documentation for a dual NK-1/serotonin receptor antagonist, 2 nonsteroidal glucocorticoid receptor modulators and a selective ErbB VEGF receptor inhibitor. Conducted the external and internal technology transfer and contributed to the preparation of regulatory documents and responses to health authorities.
  • Author or co-author on 60 manuscripts, 4 book chapters and 10 US patents. Presented nearly 20 lectures at universities and national/international conferences.


Panel Discussion: What Do Pharma Need from Outsourcing & How Can Both Sides Communicate Better to Expedite Speed to Market? 11:30 am

How can pharma better engage with CDMOs? Gaining visibility of containment solutions available at a plant to align standards across external partners Building a long-lasting relationship – from capabilities to EHS programsRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.